Discriminant Efficacy of mpMRI for Variant Pathology Associated with Prostate Adenocarcinoma

dc.authorscopusid 11839425100
dc.authorscopusid 57219463817
dc.authorscopusid 57204436831
dc.authorscopusid 58010281600
dc.contributor.author Köseoğlu,H.
dc.contributor.author Cenkeri,H.Ç.
dc.contributor.author Eroğlu,T.
dc.contributor.author Yalçın,B.
dc.date.accessioned 2024-05-25T12:18:19Z
dc.date.available 2024-05-25T12:18:19Z
dc.date.issued 2023
dc.department Okan University en_US
dc.department-temp Köseoğlu H., Health Sciences University, Hamidiye Faculty of Medicine, Istanbul Health Practice and Research Center, Department of Urology, Istanbul, Turkey; Cenkeri H.Ç., Okan University, Faculty of Medicine, Department of Radiology, Turkey; Eroğlu T., Semdinli State Hospital, Department of Urology, Hakkari, Turkey; Yalçın B., Health Sciences University, Hamidiye Faculty of Medicine, Istanbul Health Practice and Research Center, Department of Radiation Oncology, Istanbul, Turkey en_US
dc.description.abstract Purpose: Implementation of multiparametric magnetic resonance imaging (mpMRI) for prostate adenocarcinoma’s variant pathology requires awareness. The aim of this retrospective study was to investigate the discriminant efficacy of multiparametric magnetic resonance imaging modality for variant pathology associated with prostate adenocarcinoma. Methods: Consecutive 247 prostate cancer patients who underwent radical prostatectomy in our university-based hospital between October 2014 and October 2019, were retrospectively reviewed. Data of mpMRI-associated contrast enhancements, T2 signals, apparent diffusion coefficients (ADC), ages, and PSA values were compared. Clinical and demographic data of patients were noted including associated variant pathologies and reports of preoperative mpMRI images. Results: Among the patients, 63 (26%) had variant pathology and 14 (22%) had mpMRI before primary prostate biopsy. The group with variant pathology and the control group had similar perfusion curves and increased contrast when compared for mpMRI parameters, but different ADC values for each of the adjusted b-values for 400, 800 and 1400. Conclusion: Our study demonstrates that mpMRI appears to have no role in distinguishing rare variant pathologies associated with prostate adenocarcinoma despite different ADC values. © 2023, Urology Journal. All Rights Reserved. en_US
dc.identifier.citationcount 0
dc.identifier.doi 10.22037/uj.v20i.7468
dc.identifier.endpage 161 en_US
dc.identifier.issn 1735-1308
dc.identifier.issue 3 en_US
dc.identifier.pmid PubMed:36840448
dc.identifier.scopus 2-s2.0-85160458849
dc.identifier.scopusquality Q3
dc.identifier.startpage 157 en_US
dc.identifier.uri https://doi.org/10.22037/uj.v20i.7468
dc.identifier.uri https://hdl.handle.net/20.500.14517/1691
dc.identifier.volume 20 en_US
dc.identifier.wosquality Q4
dc.language.iso en
dc.publisher Urology and Nephrology Research Centre en_US
dc.relation.ispartof Urology Journal en_US
dc.relation.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.scopus.citedbyCount 0
dc.subject apparent diffusion coefficient en_US
dc.subject mpMRI en_US
dc.subject prostate adenocarcinoma en_US
dc.subject prostate cancer variants en_US
dc.title Discriminant Efficacy of mpMRI for Variant Pathology Associated with Prostate Adenocarcinoma en_US
dc.type Article en_US

Files